Bayer Signs a License and Research Agreement with Gubra to Develop Novel Peptide Therapeutics for Cardiorenal Diseases
Shots:
- Gubra to receive ~ $253.4M as up front- development- and commercialization milestones
- The collaboration will combine Gubra’s peptide drug discovery capabilities with Bayer’s expertise to develop innovative medicines to treat cardiorenal diseases
- The collaboration also use Gubra’s streaMLine which is an ML based peptide drug discovery platform & is used for fast screening and identification of potent therapeutic peptide candidates
| Ref: Gubra | Image: Crunchbase
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com